We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls
Read MoreHide Full Article
Key Takeaways
GEHC's Q3 revenues rose 6% to $5.14B, beating estimates, though EPS fell 6.1% year over year.
Strong gains in GEHC's Imaging and Pharma Diagnostics offset weakness in Patient Care Solutions.
GEHC updated 2025 EPS outlook to $4.51-$4.63, amid ongoing tariff-related headwinds.
GE HealthCare (GEHC - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.07, which beat the Zacks Consensus Estimate of $1.05 by 1.9%. However, the bottom line declined 6.1% year over year.
GAAP EPS in the quarter was 98 cents, down 3.9% from the year-ago level.
Revenue Details
Revenues of $5.14 billion were up 6% year over year on a reported basis and 4% organically. The top line beat the Zacks Consensus Estimate by 1.4%. Total company orders increased 6% organically year over year.
Revenues were driven by strength in the U.S. market as well as in the EMEA markets.
Segmental Details
Imaging
Revenues from this segment totaled $2.35 billion, up 5% year over year on a reported basis and 4% organically.
Segment EBIT was $240 million, down 16% year over year.
Advanced Visualization Solutions
Revenues totaled $1.3 billion, up 7% year over year on a reported basis and 6% on an organic basis.
Segment EBIT was $271 million, up 17% year over year.
Patient Care Solutions
Revenues amounted to $731 million, down 6% year over year on a reported basis and down 7% organically.
Segment EBIT was $27 million, down 67% year over year.
Pharmaceutical Diagnostics
Revenues totaled $749 million, up 20% year over year and 10% on an organic basis.
Segment EBIT was $220 million, up 14% year over year.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
Net income margin was 8.7%, down 100 basis points from the prior-year level, due to unfavorable impact of tariffs, partially offset by benefits from volume and price.
Cumulative cash flow from operating activities at the end of the third quarter was $937 million compared with $1.04 billion a year ago.
Financial Position
GEHC exited the third quarter with cash, cash equivalents and investments of $4.03 billion compared with $3.76 billion in the previous quarter.
Total assets increased to $36.13 billion from $35.5 billion on a sequential basis.
2025 Guidance
GE HealthCare updated its earnings guidance for 2025.
The company now expects adjusted EPS to be in the range of $4.51-$4.63 compared with the previous guidance of $4.43-$4.63. The guidance includes approximately 45 cents of unfavorable impact of tariffs. The company continues to estimate revenue growth at 3% organically. The Zacks Consensus Estimate for 2025 EPS and revenues is pegged at $4.53 and $20.45 billion, respectively.
Our Take
GE HealthCare delivered robust third-quarter results, wherein both earnings and revenues beat estimates. However, the company demonstrated steady execution and broad-based growth despite macroeconomic and tariff headwinds. Strength across Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics offset temporary softness in Patient Care Solutions, underscoring the company’s diverse and innovation-driven portfolio.
Continued investment in R&D and new product introductions, such as advanced imaging systems and AI-enabled diagnostics, reflect GE HealthCare’s commitment to driving precision care and digital transformation in clinical workflows. The company also strengthened its strategic positioning with targeted acquisitions and partnerships in radiopharmaceuticals and neuroimaging AI.
Operational efficiency efforts and disciplined pricing helped mitigate cost pressures, while robust demand and strong order growth signal durable customer confidence. By raising the lower end of its full-year earnings outlook, GE HealthCare reaffirmed its ability to deliver sustainable growth and navigate a challenging environment.
GEHC’s Zacks Rank & Stocks to Consider
GE HealthCare has a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Solventum Corporation (SOLV - Free Report) , Boston Scientific Corporation (BSX - Free Report) and HealthEquity (HQY - Free Report) .
Solventum, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 4.1%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Solventum’s shares have gained 8.2% compared with the industry’s 6.2% growth so far this year.
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.1%.
Boston Scientific’s shares have gained 13.2% compared with the industry’s 5.6% growth so far this year.
HealthEquity, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.7%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 11.05%.
HealthEquity’s shares have risen 0.6% compared with the industry’s 6.2% growth so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls
Key Takeaways
GE HealthCare (GEHC - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.07, which beat the Zacks Consensus Estimate of $1.05 by 1.9%. However, the bottom line declined 6.1% year over year.
GAAP EPS in the quarter was 98 cents, down 3.9% from the year-ago level.
Revenue Details
Revenues of $5.14 billion were up 6% year over year on a reported basis and 4% organically. The top line beat the Zacks Consensus Estimate by 1.4%. Total company orders increased 6% organically year over year.
Revenues were driven by strength in the U.S. market as well as in the EMEA markets.
Segmental Details
Imaging
Revenues from this segment totaled $2.35 billion, up 5% year over year on a reported basis and 4% organically.
Segment EBIT was $240 million, down 16% year over year.
Advanced Visualization Solutions
Revenues totaled $1.3 billion, up 7% year over year on a reported basis and 6% on an organic basis.
Segment EBIT was $271 million, up 17% year over year.
Patient Care Solutions
Revenues amounted to $731 million, down 6% year over year on a reported basis and down 7% organically.
Segment EBIT was $27 million, down 67% year over year.
Pharmaceutical Diagnostics
Revenues totaled $749 million, up 20% year over year and 10% on an organic basis.
Segment EBIT was $220 million, up 14% year over year.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
GE HealthCare Technologies Inc. price-consensus-eps-surprise-chart | GE HealthCare Technologies Inc. Quote
Margins
Net income margin was 8.7%, down 100 basis points from the prior-year level, due to unfavorable impact of tariffs, partially offset by benefits from volume and price.
Cumulative cash flow from operating activities at the end of the third quarter was $937 million compared with $1.04 billion a year ago.
Financial Position
GEHC exited the third quarter with cash, cash equivalents and investments of $4.03 billion compared with $3.76 billion in the previous quarter.
Total assets increased to $36.13 billion from $35.5 billion on a sequential basis.
2025 Guidance
GE HealthCare updated its earnings guidance for 2025.
The company now expects adjusted EPS to be in the range of $4.51-$4.63 compared with the previous guidance of $4.43-$4.63. The guidance includes approximately 45 cents of unfavorable impact of tariffs. The company continues to estimate revenue growth at 3% organically. The Zacks Consensus Estimate for 2025 EPS and revenues is pegged at $4.53 and $20.45 billion, respectively.
Our Take
GE HealthCare delivered robust third-quarter results, wherein both earnings and revenues beat estimates. However, the company demonstrated steady execution and broad-based growth despite macroeconomic and tariff headwinds. Strength across Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics offset temporary softness in Patient Care Solutions, underscoring the company’s diverse and innovation-driven portfolio.
Continued investment in R&D and new product introductions, such as advanced imaging systems and AI-enabled diagnostics, reflect GE HealthCare’s commitment to driving precision care and digital transformation in clinical workflows. The company also strengthened its strategic positioning with targeted acquisitions and partnerships in radiopharmaceuticals and neuroimaging AI.
Operational efficiency efforts and disciplined pricing helped mitigate cost pressures, while robust demand and strong order growth signal durable customer confidence. By raising the lower end of its full-year earnings outlook, GE HealthCare reaffirmed its ability to deliver sustainable growth and navigate a challenging environment.
GEHC’s Zacks Rank & Stocks to Consider
GE HealthCare has a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Solventum Corporation (SOLV - Free Report) , Boston Scientific Corporation (BSX - Free Report) and HealthEquity (HQY - Free Report) .
Solventum, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 4.1%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Solventum’s shares have gained 8.2% compared with the industry’s 6.2% growth so far this year.
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.1%.
Boston Scientific’s shares have gained 13.2% compared with the industry’s 5.6% growth so far this year.
HealthEquity, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.7%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 11.05%.
HealthEquity’s shares have risen 0.6% compared with the industry’s 6.2% growth so far this year.